Combined effect of oral famotidine and cimetidine on the survival of lethally irradiated mice: An in vivo study

Dizaj, Karim Afsar; Monfared, Ali Shabestani; Mozdarani, Hossein; Naeiji, Ali; Razzaghdoust, Abolfazl; Hajian‐Tilaki, Karimollah; Aboufazeli, Bahareh; Niksirat, Fatemeh; Borzoueisileh, Sajad

doi:10.4103/jcrt.jcrt_349_19

Cited by 2 publications

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Mast Cell Derived Histamine Negatively Regulates Hematopoiesis

Smith

Campanelli

Cordova

et al. 2022

Preprint

View full text Add to dashboard Cite

Deeper understanding of the cellular and molecular pathways regulating hematopoiesis is critical to maximize the therapeutic potential of hematopoietic stem cells (HSCs) in curative procedures including hematopoietic stem cell transplantation (HST). We have recently identified mast cells (MCs) as therapeutically-targetable components of the HSC niche. Here, we demonstrate that mice lacking MCs display peripheral neutrophilia, expansion of bone marrow (BM) HSC populations, resistance to repeated 5-fluorouracil (5-FU) administration, and a BM genetic signature primed for hematopoietic proliferation. MC deficiency functionally altered both the hematopoietic and the stromal compartment of the BM as hematopoietic reconstitution was accelerated in wildtype mice that received MC deficient BM and in MC deficient recipients that received wildtype BM. Finally, we demonstrate that mice treated at steady state with the MC stabilizing agent ketotifen exhibit increased BM cellularity as well as expansion of phenotypic HSC populations. This work provides novel mechanistic rationale to explore mast cells as a target to enhance human BM transplants. Additionally, the potential of repurposing FDA approved mast cell targeting therapies to promote hematopoietic regeneration may provide well-tolerated treatment strategies at a fraction of the cost and development time.

show abstract

Mast Cell Derived Histamine Negatively Regulates Hematopoiesis

Smith

Campanelli

Cordova

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

Effectiveness of oral famotidine in reducing the hematologic complications of radiotherapy in patients with esophageal and cardia cancers: a randomized controlled trial

Moghaddam

2023

Radiat Oncol

View full text Add to dashboard Cite

Background Chemoradiotherapy complications has always been of great concern to both clinicians and patients during the course of treatment. The purpose of the present study was to examine the effectiveness of oral famotidine on the reduction of hematologic complications of patients with esophageal and gastric cardia cancers undergoing radiotherapy. Methods A single-blind controlled trial was conducted on 60 patients with esophageal and cardia cancers, who were undergoing chemoradiotherapy. Patients were randomly assigned to 2 groups with 30 patients to receive either 40 mg of oral famotidine (daily and 4 h before each session) or placebo. Complete blood count with differential, platelet counts, and hemoglobin levels were obtained weekly during treatment. The main outcome variables were lymphocytopenia, granulocytopenia, thrombocytopenia, and anemia. Results The findings indicated a significant effect of famotidine on reduction of thrombocytopenia among intervention group compared to control group (P < 0.0001). Even so, the effect of intervention was not significant for other outcome variables (All, P ≥ 0.05). The lymphocyte (P = 0.007) and platelet (P = 0.004) counts were also significantly greater in famotidine group in comparison with placebo group at the end of the study. Conclusion As evidenced by the findings of the current study, famotidine might be recommended as an effective radioprotective agent among patients with esophageal and gastric cardia cancers to prevent Leukocyte and platelet reduction to some extent. Trial registration This study was prospectively registered at irct.ir (Iranian Registry of Clinical Trials) with the code IRCT20170728035349N1, 2020-08-19.

show abstract

Combined effect of oral famotidine and cimetidine on the survival of lethally irradiated mice: An in vivo study

Cited by 2 publications

References 13 publications

Mast Cell Derived Histamine Negatively Regulates Hematopoiesis

Mast Cell Derived Histamine Negatively Regulates Hematopoiesis

Effectiveness of oral famotidine in reducing the hematologic complications of radiotherapy in patients with esophageal and cardia cancers: a randomized controlled trial

Contact Info

Product

Resources

About